TS
Travis Steed Barclays Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Becton Dickinson
BDX
$55.1B
| $192.39 | $261 |
36%
upside
| Overweight |
7 Apr ‘25
5 months ago |
|
2
Penumbra
PEN
$11B
| $281.46 | $320 |
14%
upside
| Buy |
14 Mar ‘25
5 months ago |
|
3
Abbott
ABT
$231B
| $132.94 | $150 |
13%
upside
| Buy |
10 Mar ‘25
6 months ago |
|
4
Solventum
SOLV
$12.6B
| $72.72 | $85 |
17%
upside
| Neutral |
26 Feb ‘25
6 months ago |
|
5
Edwards Lifesciences
EW
$47.5B
| $80.94 | $90 |
11%
upside
| Buy |
16 Dec ‘24
8 months ago |
|
|
CBLL
6
CeriBell, Inc. Common Stock
CBLL
$433M
| $11.80 | $32 |
171%
upside
| Buy |
5 Nov ‘24
10 months ago |
|
7
Baxter International
BAX
$12.5B
| $24.42 | $45 |
84%
upside
| Neutral |
5 Mar ‘24
1 year ago |
|
8
Outset Medical
OM
$249M
| $14.01 | $45 |
221%
upside
| Underperform |
13 Oct ‘23
1 year ago |
|
9
Stryker
SYK
$150B
| $392.31 | $315 |
20%
downside
| Buy |
5 Sep ‘23
2 years ago |
|
10
Insulet
PODD
$24.5B
| $348.43 | $295 |
15%
downside
| Buy |
24 Aug ‘23
2 years ago |
|
11
Axogen
AXGN
$735M
| $15.98 | $16 |
0%
upside
| Overweight |
22 Aug ‘23
2 years ago |
|
12
Tandem Diabetes Care
TNDM
$850M
| $12.58 | $33 |
162%
upside
| Underperform |
5 May ‘23
2 years ago |
|
13
Zimmer Biomet
ZBH
$20.9B
| $105.73 | $160 |
51%
upside
| Neutral |
3 May ‘23
2 years ago |
|
14
Intuitive Surgical
ISRG
$167B
| $466.86 | $315 |
33%
downside
| Buy |
19 Apr ‘23
2 years ago |
|
|
15
Becton Dickinson
BDX
$55.1B
| $192.39 | $290 |
51%
upside
| Buy |
3 Jan ‘23
2 years ago |
|
16
Pulmonx
LUNG
$70.9M
| $1.74 | $8 |
360%
upside
| Underperform |
3 Jan ‘23
2 years ago |
|
17
Embecta
EMBC
$875M
| $14.96 | $25 |
67%
upside
| Underperform |
21 Jun ‘22
3 years ago |
|
18
InMode
INMD
$947M
| $14.98 | $85 |
467%
upside
| Overweight |
13 Oct ‘21
3 years ago |
|
|
19
Zimmer Biomet
ZBH
$20.9B
| $105.73 | $186 |
76%
upside
| Overweight |
5 Oct ‘21
3 years ago |
|
|
20
Baxter International
BAX
$12.5B
| $24.42 | $100 |
310%
upside
| Overweight |
3 Sep ‘21
4 years ago |
|
|
21
Abbott
ABT
$231B
| $132.94 | $125 |
6%
downside
| Overweight |
2 Jun ‘21
4 years ago |
|
22
DexCom
DXCM
$31.6B
| $80.51 | $125 |
55%
upside
| Overweight |
25 May ‘21
4 years ago |
|
23
Medtronic
MDT
$119B
| $92.90 | $145 |
56%
upside
| Equal-Weight |
25 May ‘21
4 years ago |
|
24
Boston Scientific
BSX
$159B
| $107.22 | $51 |
52%
downside
| Overweight |
25 May ‘21
4 years ago |
|
|
25
Edwards Lifesciences
EW
$47.5B
| $80.94 | $110 |
36%
upside
| Overweight |
25 May ‘21
4 years ago |
|